The world that we live in is filled with sounds, some are comforting and some could be jarring too. But what if the constant noise surrounding us is doing us more harm than we realize? There has been immense research that shows that noise is not just a nuisance, but a silent killer and affects our health in ways we do not even know. There are associations of sound causing heart attacks, type 2 diabetes, and dementia.

How Does Your Body Respond To Noise?

Noise is seen as an annoyance, but it effects can go beyond what we imagine. When we hear a sound, it travels through the ear to the brain. This is where it gets processed by the amygdala. It is a region that is responsible for emotional responses. This also triggers a stress response- our heart rate increases, our blood pressure rises, and stress hormones like cortisol flood our system.

This response is also designed to help us react to immediate threats. Especially, if we hear the sound of a predator approaching. However, when we are exposed to constant noise, this response is triggered repeatedly and could compel us to live in a long-term anxious state.

Hidden Health Risks

Many studies including Harvard Health and theAmerican College of Cardiology have found associations of noise with health problems including putting a person at a higher risk of cardiovascular diseases such as heart strokes, attacks, and high blood pressure. The constant activation of the stress response can take a toll on the body, increasing inflammation and making it harder for the heart and circulatory system to function properly. Over time, this can lead to serious health conditions like heart disease and diabetes.

Even more troubling, research suggests that noise pollution may contribute to mental health issues. Studies have found a strong connection between exposure to noise and disturbed sleep, which in turn can cause anxiety, depression, and cognitive decline. The World Health Organization estimates that noise contributes to around 12,000 premature deaths annually across Europe alone. This invisible threat, however, is often overlooked because the effects are gradual and cumulative.

Noise and Sleep: A Silent Disturbance

One of the most insidious aspects of noise pollution is its impact on sleep. Even when we are asleep, our bodies are not fully immune to the effects of sound. Our ears never fully “turn off,” meaning that even faint noises can disrupt our sleep cycle. Research has shown that people who live in noisy environments—whether near busy roads, airports, or urban centers—often experience fragmented sleep, leading to fatigue and a weakened immune system. Over time, this chronic lack of restful sleep can lead to significant health problems, including an increased risk of developing cognitive disorders such as dementia.

The Urbanization Problem

As cities continue to grow, noise pollution is becoming more widespread. Traffic noise, in particular, is one of the most common and harmful sources. The rise of urbanization means more cars, buses, and trains, all of which contribute to an ever-increasing din. This urban soundscape is often relentless, with little respite for those living within it. In densely populated cities, people are exposed to high decibel levels, which can exceed safe thresholds for heart health. In many cases, the sheer volume of sound is not just unpleasant; it’s dangerous.

What Can We Do About It?

The solution is not as simple as reducing noise in our immediate surroundings, though efforts to reduce traffic noise and limit industrial sounds are essential. Some cities have taken steps to create quieter spaces by converting busy roads into pedestrian zones or installing noise barriers. These measures have shown to have a positive impact on public health, with research suggesting that even small reductions in noise can prevent premature deaths and improve overall well-being.

Metabolism-Associated Fatty Liver Disease (MAFLD) — also termed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — is defined by excess hepatic fat accumulation (>5 per cent of liver weight) in the presence of metabolic dysfunction, independent of alcohol intake. It encompasses a spectrum from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.

MAFLD: Epidemiology In India

A Lancet Regional Health study found that approximately 39 per cent of Indian adults screened had fatty liver disease, making it one of the most prevalent chronic liver conditions in the country. Within India, prevalence shows regional variation driven by genetic, dietary, and socioeconomic factors.

A particularly important feature is the “lean MAFLD” phenotype — South Asians often develop fatty liver at a lower BMI due to disproportionately high visceral fat, which complicates detection based on conventional BMI screening. Currently, MASLD is the commonest cause of liver cirrhosis and hepatocellular carcinoma (HCC).

MAFLD: Causes And Risk Factors

The core drivers are components of metabolic syndrome: type 2 diabetes mellitus, obesity (particularly central adiposity), dyslipidemia, hypertension, and insulin resistance. MASLD is strongly linked to obesity, sedentary lifestyles, and metabolic syndrome.

Genetic susceptibility also plays a role — variants in genes such as PNPLA3 are associated with increased liver fat accumulation, particularly in certain Indian populations. Rapid dietary transition towards ultra-processed, high-calorie foods compounds the risk.

MAFLD: Investigations

Routine liver function tests may appear normal in early stages, and an ultrasound detects only moderate-to-severe fat accumulation. A structured approach includes:

• Blood tests: LFTs, fasting glucose, HbA1c, lipid profile, insulin resistance indices
• Ultrasound abdomen: First-line imaging for steatosis
• FibroScan (Transient Elastography): Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) are standardized non-invasive tools for assessing fibrosis and steatosis.
• Liver biopsy: Gold standard for staging steatohepatitis and fibrosis when non-invasive tests are inconclusive.

MAFLD: Treatment

No approved pharmacotherapy exists exclusively for MAFLD; management is lifestyle-centred:

• Weight loss: 7–10 per cent body weight reduction significantly reduces hepatic steatosis and inflammation
• Diet: Mediterranean-style diet; restrict refined carbohydrates and saturated fats
• Exercise: Both aerobic and resistance training improve insulin sensitivity and liver fat
• Metabolic comorbidity control: Optimise glycaemia (GLP-1 agonists show hepatic benefit), manage dyslipidaemia and hypertension
• Emerging therapies: Resmetirom (thyroid hormone receptor-β agonist) has shown promise in MASH with fibrosis.

Once known to affect only people over 60, Parkinson’s Disease is now increasingly being seen in young adults, especially at the age of 40, said health experts on World Parkinson’s Day today.

World Parkinson’s Day is observed every year on April 11 to raise awareness about the brain condition that causes tremors, slowness of movement, and trouble walking.

Parkinson’s is a progressive and neurodegenerative movement disorder caused by the loss of dopamine-producing brain cells.

Progressive decline in mobility is a key issue among Parkinson's patients, impacting their independence and quality of life. Other problems include slow movement, tremor, imbalance, cognitive impairment, mental health disorders, sleep disorders, and pain.

Also read: World Parkinson's Day 2026: Origin, Theme And Global Burden

Young-onset Parkinson’s Disease

According to the American Parkinson's Disease Association, a diagnosis of Parkinson’s between the ages of 21 and 50 is referred to as early-onset Parkinson’s disease, or young-onset Parkinson’s disease (YOPD).

Exposure to environmental toxins and lifestyle changes are major reasons for the rise in Parkinson's in this group.

While the symptoms of the disease are mostly the same at whatever age it develops, younger people will experience the disease differently due to their unique life circumstances. Managing the disease can be particularly challenging for a younger person and their family from a medical, psychological, and social standpoint.

"There is a perceived increase in younger-onset Parkinson’s in India. Possible reasons include better awareness and diagnosis (more neurologists, improved access to care), environmental exposures (pesticides, heavy metals), and air/water pollution. Lifestyle (sedentary habits) and urbanization-related factors may also contribute," Dr Sudhir Kumar, Neurologist at Apollo Hospitals Hyderabad, told HealthandMe.

A 2022 study, published in NPJ Parkinson's Disease, showed that the incidence of Parkinson’s disease, or the number of new cases diagnosed per year, is 50 per cent higher than previously estimated.

Instead of past estimates of 60,000 new cases of Parkinson’s disease diagnosed per year, the study determined that there are approximately 90,000 new cases of Parkinson's disease diagnosed in the US per year.

"Young-onset Parkinson’s disease (YOPD) is on the rise, mainly in the middle socio-demographic index. These countries include India, China, and some Southeast Asian countries," Dr Paresh Doshi, Director of Neurosurgery and Stereotactic & Functional Neurosurgery at Jaslok Hospital and Research Centre.

"According to one research paper, the age-standardized incidence rate has been rising at an alarming rate of 1.4 per cent per annum. To put it in perspective, if the incidence was 100/10,00,000 in 1995, it would be 153/10,00,000 in 2026," he added.

The experts noted that, along with the rising disability burden, mortality is reducing. The compound effect of all these is a larger number of YOPD patients suffering longer. Surgeries like deep-brain stimulation can help reduce these disabilities significantly.

Checklist for Parkinson’s: Signs You Should Not Ignore

Early recognition is critical, as many symptoms precede motor features by years.

Common early signs include:

• Reduced sense of smell (anosmia)
• Slowness of movement (bradykinesia)
• Reduced arm swing while walking
• Resting tremor
• Masked facies (reduced facial expression)
• Change in handwriting (micrographia)

Other important symptoms, which are often overlooked:

• Constipation
• Sleep disturbances (especially REM sleep Behavior disorder)
• Depression or anxiety.

Parkinson’s Disease is traditionally characterized by motor symptoms such as tremor and dyskinesia, although non-motor symptoms, in particular gastrointestinal (GI) symptoms such as constipation and incomplete emptying, are often the first markers of the disease and may precede the motor symptoms by years.

GI dysfunction is reported in approximately 70-80 per cent of Parkinson’s patients, mediated in large part through the gut-brain axis (GBA).

Speaking to HealthandMe, Dr Paresh Doshi, Director of Neurosurgery and Stereotactic and Functional Neurosurgery at Jaslok Hospital and Research Center, GBA, is an established two-way network that links the GI tract and the central nervous system (CNS). The connection is multifaceted, involving the vagus nerve, the enteric nervous system (ENS), the immune system, and a vast number of microbial metabolites and neuroendocrine signals.

“Constipation is seen in 66 per cent of Parkinson’s patients, attributed to disordered central and peripheral parasympathetic disruption, and can lead to alteration of the gut microbiome, which in turn worsens constipation, starting a feedback loop,” the doctor explained.

What Parkinson’s Patients Must Eat

Dr Sudhir Kumar, Neurologist at Apollo Hospitals Hyderabad, told HealthandMe that changes in the gut microbiome may influence inflammation, α-synuclein aggregation, and symptom progression.

Practical dietary principles for Parkinson’s patients include:

• Prefer fiber-rich, plant-based foods (vegetables, fruits, whole grains), which support gut microbiota
• Include fermented foods (curd, buttermilk), which may improve microbial diversity
• Reduce ultra-processed and pro-inflammatory foods
• Ensure adequate hydration (helps reduce the risk of constipation, a common non-motor symptom)
• Protein timing matters: Levodopa competes with amino acids for absorption.

These gut-targeted interventions are promising adjuncts to conventional Parkinson's therapy, and improving patient quality of life.

Parkinson’s Treatment With Dance, Art

Beyond gut-brain axis, research has proven that unconventional therapy, like dance and art, can improve Parkinson’s treatment.

A 2024 study published in the Scientific Reports found that tango, particularly Argentine tango, improved Parkinson's symptoms like thinking problems or balance issues. It also led to a significant improvement in recognizing emotions on people's faces.

Dr Kumar said dance therapy improves balance, gait, and coordination; provides rhythmic cueing, which enhances motor performance, and improves mood and motivation (dopamine-related pathways).

Similarly, art therapy has been shown to improve overall visual-cognitive skills and visual exploration strategies as well as general motor function in patients with Parkinson’s. The changes in brain connectivity highlight a functional reorganization of visual networks, as revealed by a study published in Parkinsonism & Related Disorders.

Dr Kumar said art and creative therapies are also helpful in enhancing cognitive engagement. It may help with executive function and emotional well-being and provide a non-verbal outlet for expression. However, these therapies work best as adjuncts, not replacements, to standard treatment, the expert noted.

World Parkinson’s Day 2026

World Parkinson's Day is observed annually on April 11 to raise global awareness of Parkinson’s disease, the world's fastest-growing neurodegenerative disorder.

It highlights the need for early diagnosis, research, and support for the nearly 10 million people living with the condition. The day marks the birthday of Dr. James Parkinson, who first described the disease in 1817.

The theme of World Parkinson's Day 2026 is "Bridge the Care Gap." It reflects a critical challenge that persists despite advances in medical research: many people living with Parkinson's still lack consistent access to specialist care, affordable treatment, and integrated support systems.

Parkinson's disease affected 11.9 million people in 2021 and will affect 25.2 million people globally by 2050, representing an alarming 112 per cent rise.